Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albinterferon alfa-2b regimens every 4 weeks plus ribavirin versus peginterferon alfa-2a plus ribavirin in chronic hepatitis C
2006-006803-35Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of albinterferon alfa-2b in hepatitis C virus infection (5 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of albinterferon alfa-2b Q4w regimens and Antiviral efficacy of albinterferon alfa-2b Q4w regimens. Started Mar 2008; status: terminated.
02
Drugs
albinterferon alfa-2b
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-006803-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006803-35.